Literature DB >> 2959374

Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.

D A Nikcevich1, G P Duffie, M R Young, N K Ellis, G E Kaufman, H T Wepsic.   

Abstract

Systemic administration of a single dose (300 mg/kg) of cyclophosphamide (Cy) induced the appearance of a population of suppressor cells in the bone marrow and spleens of mice. Suppressor cells were assayed by their capacity to inhibit the concanavalin A (Con A) blastogenesis or the mixed-lymphocyte response of normal C57Bl/6 spleen cells. Cy-induced bone marrow (Cy-BM) suppressor cells were present as early as 4 days following Cy therapy and their activity gradually decreased over the next 2 weeks. Cy-induced splenic (Cy-Sp) suppressor cells were maximally present on Days 6 through 10 following Cy therapy. Studies were performed to characterize the suppressor cells of bone marrow obtained 4 days after Cy treatment and of normal bone marrow (N-BM). Some suppressor activity was present in normal bone marrow. N-BM suppressor cells resembled cells of the monocyte/macrophage lineage in that they were slightly adherent to Sephadex G-10, sensitive to L-leucine methyl ester (LME), and insensitive to treatment either with anti-T-cell antibody and complement or with anti-immunoglobulin antibody and complement. Their suppressive activity was abrogated by incubation with either indomethacin or catalase. Cy-BM suppressor cells were also resistant to treatment with anti-T-cell and anti-immunoglobulin antibody and complement but were not adherent to Sephadex G-10 and not sensitive to LME. Their suppressive activity was partially eliminated by indomethacin alone or in combination with catalase. We conclude that Cy chemotherapy induces the appearance of a population of immune suppressive cells and that these cells appear first in the bone marrow and subsequently in the spleen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959374     DOI: 10.1016/0008-8749(87)90318-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

Authors:  Zhi-Chun Ding; Xiaoyun Lu; Miao Yu; Henrique Lemos; Lei Huang; Phillip Chandler; Kebin Liu; Matthew Walters; Antoni Krasinski; Matthias Mack; Bruce R Blazar; Andrew L Mellor; David H Munn; Gang Zhou
Journal:  Cancer Res       Date:  2014-04-29       Impact factor: 12.701

Review 2.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

3.  Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.

Authors:  J A Wise; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Myeloid-derived suppressor cells: a novel therapeutic target.

Authors:  Jennifer S Ko; Ronald M Bukowski; James H Fincke
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

5.  Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 6.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

7.  The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity.

Authors:  Zhi-Chun Ding; Nada S Aboelella; Locke Bryan; Huidong Shi; Gang Zhou
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.